JAZZ Jazz Pharmaceuticals PE ratio, current and historical analysis
As at Apr 2, 2025, the JAZZ stock has a price-to-earnings ratio of 13.96. This is based on the current EPS of $9.06 and the stock price of $126.44 per share. A decrease of 19% has been recorded in the PE ratio compared to the average of 17.1 of the last four quarters.
JAZZ PE ratio history
The mean historical PE ratio of Jazz Pharmaceuticals over the last ten years is 29.73. The current 13.96 P/E ratio is 53% lower than the historical average. In the past ten years, JAZZ's PE ratio peaked in the Jun 2021 quarter at 160.04, with a price of $177.64 and an EPS of $1.11. The Sep 2019 quarter marked the lowest point at 12.11, with a price of $128.14 and an EPS of $10.58.
Jazz Pharmaceuticals PE ratio by year
Maximum annual increase: 389.8% in 2014
Maximum annual decrease: -84.36% in 2015
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 13.59 | -27.64% | $123.15 | $9.06 |
| 2023 | 18.78 | N/A | $123 | $6.55 |
| 2022 | N/A | N/A | $159.31 | -$3.58 |
| 2021 | N/A | N/A | $127.4 | -$5.52 |
| 2020 | 38.56 | 138.17% | $165.05 | $4.28 |
| 2019 | 16.19 | -2.7% | $149.28 | $9.22 |
| 2018 | 16.64 | 0.48% | $123.96 | $7.45 |
| 2017 | 16.56 | -0.36% | $134.65 | $8.13 |
| 2016 | 16.62 | -36.39% | $109.03 | $6.56 |
| 2015 | 26.13 | -84.36% | $140.56 | $5.38 |
| 2014 | 167.07 | 389.8% | $163.73 | $0.98 |
| 2013 | 34.11 | 226.1% | $126.56 | $3.71 |
| 2012 | 10.46 | -18.47% | $53.25 | $5.09 |
| 2011 | 12.83 | -41.34% | $38.63 | $3.01 |
| 2010 | 21.87 | N/A | $19.68 | $0.9 |
Jazz Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 13.59 | -9.1% | $123.15 | $9.06 |
| Sep 2024 | 14.95 | -12.06% | $111.41 | $7.45 |
| Jun 2024 | 17 | -26.15% | $106.73 | $6.28 |
| Mar 2024 | 23.02 | 22.58% | $120.42 | $5.23 |
| Dec 2023 | 18.78 | -82.59% | $123 | $6.55 |
| Sep 2023 | 107.87 | N/A | $129.44 | $1.2 |
| Jun 2023 | N/A | N/A | $123.97 | -$1.44 |
| Mar 2023 | N/A | N/A | $146.33 | -$2.51 |
| Dec 2022 | N/A | N/A | $159.31 | -$3.58 |
| Sep 2022 | N/A | N/A | $133.29 | -$0.26 |
| Jun 2022 | N/A | N/A | $156.01 | -$0.81 |
| Mar 2022 | N/A | N/A | $155.67 | -$7.48 |
| Dec 2021 | N/A | N/A | $127.4 | -$5.52 |
| Sep 2021 | N/A | N/A | $130.21 | -$2.42 |
| Jun 2021 | 160.04 | 804.69% | $177.64 | $1.11 |
JAZZ average PE ratio chart
The current PE ratio of JAZZ is lower than the 3, 5 and 10-year averages.
JAZZ PE vs peers
In comparison to its peer stock NVS, JAZZ's PE ratio is lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | 13.96 | $7.68B |
| NVS Novartis AG | 18.71 | $218.78B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $17.34B |
| PRGO PERRIGO Co plc | N/A | $3.81B |
| SAGE Sage Therapeutics Inc | N/A | $477.71M |
Frequently asked questions
What is Jazz Pharmaceuticals's PE ratio?
The price to earnings ratio for JAZZ stock as of Apr 2, 2025, stands at 13.96.
What is the 3-year average PE ratio for Jazz Pharmaceuticals (JAZZ)?
The 3-year average price to earnings ratio for JAZZ stock is 32.54.
What is the 5-year average PE ratio for Jazz Pharmaceuticals (JAZZ)?
The 5-year average price to earnings ratio for JAZZ stock is 45.64.
What is the highest PE ratio for JAZZ?
In the last ten years, the Jun 2021 quarter recorded the highest quarterly PE ratio at 160.04.
How does the current PE ratio for JAZZ compare to its historical average?
JAZZ's current price to earnings ratio is 53% below its 10-year historical average.
How is JAZZ's PE ratio calculated (Jazz Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Apr 2, 2025), Jazz Pharmaceuticals's stock price is $126.44. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $9.06. Therefore, Jazz Pharmaceuticals's PE ratio for today is 13.96. PE RATIO(13.96) = STOCK PRICE($126.44) / TTM EPS($9.06)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.